المؤلفون: Toshiya Fujisaki (11476324), Satoshi Watanabe (103008), Takeshi Ota (1874704), Kohei Kushiro (11476327), Yusuke Sato (482551), Miho Takahashi (2150686), Aya Ohtsubo (649207), Satoshi Shoji (649205), Koichiro Nozaki (649204), Kosuke Ichikawa (4401235), Satoshi Hokari (11476330), Rie Kondo (3488360), Takao Miyabayashi (11476333), Tetsuya Abe (837082), Satoru Miura (649209), Hiroshi Tanaka (3087), Masaaki Okajima (649208), Masaki Terada (321073), Naoya Matsumoto (284135), Takashi Ishida (69157), Akira Iwashima (11476336), Kazuhiro Sato (751330), Hirohisa Yoshizawa (412410), Nobumasa Aoki (4401232), Masachika Hayashi (6585350), Yasuyoshi Ohshima (4401247), Toshiyuki Koya (3488357), Toshiaki Kikuchi (183766)

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, drug therapy, immune-related adverse event, immunology, NSCLC, PD-1

Relation: https://figshare.com/articles/presentation/Presentation_1_The_Prognostic_Significance_of_the_Continuous_Administration_of_Anti-PD-1_Antibody_via_Continuation_or_Rechallenge_After_the_Occurrence_of_Immune-Related_Adverse_Events_pptx/16676131

الاتاحة: https://doi.org/10.3389/fonc.2021.704475.s001

المؤلفون: Toshiya Fujisaki (11476324), Satoshi Watanabe (103008), Takeshi Ota (1874704), Kohei Kushiro (11476327), Yusuke Sato (482551), Miho Takahashi (2150686), Aya Ohtsubo (649207), Satoshi Shoji (649205), Koichiro Nozaki (649204), Kosuke Ichikawa (4401235), Satoshi Hokari (11476330), Rie Kondo (3488360), Takao Miyabayashi (11476333), Tetsuya Abe (837082), Satoru Miura (649209), Hiroshi Tanaka (3087), Masaaki Okajima (649208), Masaki Terada (321073), Naoya Matsumoto (284135), Takashi Ishida (69157), Akira Iwashima (11476336), Kazuhiro Sato (751330), Hirohisa Yoshizawa (412410), Nobumasa Aoki (4401232), Masachika Hayashi (6585350), Yasuyoshi Ohshima (4401247), Toshiyuki Koya (3488357), Toshiaki Kikuchi (183766)

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, drug therapy, immune-related adverse event, immunology, NSCLC, PD-1

Relation: https://figshare.com/articles/presentation/Presentation_2_The_Prognostic_Significance_of_the_Continuous_Administration_of_Anti-PD-1_Antibody_via_Continuation_or_Rechallenge_After_the_Occurrence_of_Immune-Related_Adverse_Events_pptx/16676134

الاتاحة: https://doi.org/10.3389/fonc.2021.704475.s002

المؤلفون: Toshiya Fujisaki (11476324), Satoshi Watanabe (103008), Takeshi Ota (1874704), Kohei Kushiro (11476327), Yusuke Sato (482551), Miho Takahashi (2150686), Aya Ohtsubo (649207), Satoshi Shoji (649205), Koichiro Nozaki (649204), Kosuke Ichikawa (4401235), Satoshi Hokari (11476330), Rie Kondo (3488360), Takao Miyabayashi (11476333), Tetsuya Abe (837082), Satoru Miura (649209), Hiroshi Tanaka (3087), Masaaki Okajima (649208), Masaki Terada (321073), Naoya Matsumoto (284135), Takashi Ishida (69157), Akira Iwashima (11476336), Kazuhiro Sato (751330), Hirohisa Yoshizawa (412410), Nobumasa Aoki (4401232), Masachika Hayashi (6585350), Yasuyoshi Ohshima (4401247), Toshiyuki Koya (3488357), Toshiaki Kikuchi (183766)

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, drug therapy, immune-related adverse event, immunology, NSCLC, PD-1

Relation: https://figshare.com/articles/dataset/Table_2_The_Prognostic_Significance_of_the_Continuous_Administration_of_Anti-PD-1_Antibody_via_Continuation_or_Rechallenge_After_the_Occurrence_of_Immune-Related_Adverse_Events_docx/16676140

الاتاحة: https://doi.org/10.3389/fonc.2021.704475.s004

المؤلفون: Toshiya Fujisaki (11476324), Satoshi Watanabe (103008), Takeshi Ota (1874704), Kohei Kushiro (11476327), Yusuke Sato (482551), Miho Takahashi (2150686), Aya Ohtsubo (649207), Satoshi Shoji (649205), Koichiro Nozaki (649204), Kosuke Ichikawa (4401235), Satoshi Hokari (11476330), Rie Kondo (3488360), Takao Miyabayashi (11476333), Tetsuya Abe (837082), Satoru Miura (649209), Hiroshi Tanaka (3087), Masaaki Okajima (649208), Masaki Terada (321073), Naoya Matsumoto (284135), Takashi Ishida (69157), Akira Iwashima (11476336), Kazuhiro Sato (751330), Hirohisa Yoshizawa (412410), Nobumasa Aoki (4401232), Masachika Hayashi (6585350), Yasuyoshi Ohshima (4401247), Toshiyuki Koya (3488357), Toshiaki Kikuchi (183766)

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, drug therapy, immune-related adverse event, immunology, NSCLC, PD-1

Relation: https://figshare.com/articles/dataset/Table_3_The_Prognostic_Significance_of_the_Continuous_Administration_of_Anti-PD-1_Antibody_via_Continuation_or_Rechallenge_After_the_Occurrence_of_Immune-Related_Adverse_Events_docx/16676143

الاتاحة: https://doi.org/10.3389/fonc.2021.704475.s005

المؤلفون: Toshiya Fujisaki (11476324), Satoshi Watanabe (103008), Takeshi Ota (1874704), Kohei Kushiro (11476327), Yusuke Sato (482551), Miho Takahashi (2150686), Aya Ohtsubo (649207), Satoshi Shoji (649205), Koichiro Nozaki (649204), Kosuke Ichikawa (4401235), Satoshi Hokari (11476330), Rie Kondo (3488360), Takao Miyabayashi (11476333), Tetsuya Abe (837082), Satoru Miura (649209), Hiroshi Tanaka (3087), Masaaki Okajima (649208), Masaki Terada (321073), Naoya Matsumoto (284135), Takashi Ishida (69157), Akira Iwashima (11476336), Kazuhiro Sato (751330), Hirohisa Yoshizawa (412410), Nobumasa Aoki (4401232), Masachika Hayashi (6585350), Yasuyoshi Ohshima (4401247), Toshiyuki Koya (3488357), Toshiaki Kikuchi (183766)

مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, drug therapy, immune-related adverse event, immunology, NSCLC, PD-1

Relation: https://figshare.com/articles/dataset/Table_1_The_Prognostic_Significance_of_the_Continuous_Administration_of_Anti-PD-1_Antibody_via_Continuation_or_Rechallenge_After_the_Occurrence_of_Immune-Related_Adverse_Events_docx/16676137

الاتاحة: https://doi.org/10.3389/fonc.2021.704475.s003